Pfizer, a major American pharmaceutical corporation, has announced that it could have a COVID-19 vaccine ready for emergency use by fall and for broader roll out by the end of the year.
According to CNN, a German biotech company working with Pfizer began its first human trials of the vaccine this week. They plan to test the experimental vaccine in the United States by next week, pending regulatory approval.
“Twelve study participants have been vaccinated with the vaccine candidate BNT162 in Germany since the start of the study on April 23, 2020,” Mainz-based BioNTech reported in a statement.
The company added that about 200 volunteers between the ages of 18 and 55 will be given doses ranging from 1µg (microgram) to 100µg “to find the optimal dose for further studies.”
Should the results of the trials come out favorably, the 2 companies are prepared to produce millions of doses in a matter of months.
“The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020, subject to technical success of the development program and approval by regulatory authorities, and the potential to rapidly scale up the capacity to produce hundreds of millions of doses in 2021,” Pfizer announced in its first-quarter report.
However, there is no information available on the results of the trial yet.
What do you think about this?
Do you have a story for the WhenInManila.com Team? Email us at email@example.com or send us a direct message at WhenInManila.com Facebook Page. Interact with the team and join the WhenInManila.com Community at WIM Squad! Join our WhenInManila.com community on Viber, as well!